>"Molnupiravir’s approval comes a day after the FDA cleared a more effective competing antiviral pill from Pfizer."

Effective at-home antiviral drugs designed to prevent or treat COVID-19 could be key pandemic-fighting tools, especially _...Read More_

>"The F.D.A. said the drug was not a preferred treatment, but could be used when alternate treatment options were “not accessible or clinically appropriate.”"

"As the world worries that the Omicron coronavirus variant may cause a surge of cases and weaken vaccines, drug developers have some encouraging news: Two new Covid-19 pills are coming soon, and are expected to work against all versions of _...Read More_

>"New antiviral drugs are startlingly effective against the coronavirus—if they’re taken in time."

>"In the fall of 2015, Dr. Mark Denison was preparing for a long drive home from Alabama after making a presentation at a scientific meeting when a colleague asked him to stick around for lunch and check out some data on a potential new _...Read More_

The deal could help significantly expand access to the Covid-19 treatment, but the agreement excludes a number of countries hit hard by the pandemic.

The antiviral pills are “for people that already they get the disease. This is for sick people, the goal here is to prevent people from getting sick,” Bourla _...Read More_

The authorization of Merck’s easy-to-use Covid treatment, molnupiravir, is a step toward taming the pandemic.

"The agreement will allow the Medicines Patent Pool to grant further licenses to qualified companies who are approved to make the drug. Neither drug maker will receive royalties under the agreement for as long as the World Health _...Read More_

"The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations."

[https://edition.cnn.com/2021/10/01/health/us-coronavirus-friday/index.html](https://edition.cnn.com/2021/10/01/health/us-coronavirus-friday/index.html) >"A pill has cut the risk of hospitalization or death from Covid-19 by half in a study, Merck and Ridgeback Biotherapeutics said Friday."